Buscar
vTv Therapeutics Inc
VTVTAñadir a la lista de seguimiento
30.450USD
-0.130-0.42%
Horarios del mercado 09/24, 10:08（ET）
119.97MCap. mercado
PérdidaP/E TTM
Acerca de vTv Therapeutics Inc Compañía
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.
Perfil de vTv Therapeutics Inc
Símbolo de cotizaciónVTVT
Nombre de la empresavTv Therapeutics Inc
Fecha de salida a bolsaJul 30, 2015
Director ejecutivoSekhri (Paul Jai)
Número de empleados23
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 30
Dirección3980 Premier Dr
CiudadHIGH POINT
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal27265
Teléfono13368410300
Sitio Webhttps://vtvtherapeutics.com/
Símbolo de cotizaciónVTVT
Fecha de salida a bolsaJul 30, 2015
Director ejecutivoSekhri (Paul Jai)
Ejecutivos de vTv Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Srinivas Akkaraju, M.D., Ph.D.
Dr. Srinivas Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
5.23K
--
Dr. Srinivas Akkaraju, M.D., Ph.D.
Dr. Srinivas Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
5.23K
--
Dr. Srinivas Akkaraju, M.D., Ph.D.
Dr. Srinivas Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
5.23K
--
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Independent Director
Independent Director
5.01K
+57.13%
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Independent Director
Independent Director
5.01K
+57.13%
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Independent Director
Independent Director
5.01K
+57.13%
Mr. Paul Jai Sekhri
Mr. Paul Jai Sekhri
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
5.00K
--
Mr. Paul Jai Sekhri
Mr. Paul Jai Sekhri
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
5.00K
--
Mr. Paul Jai Sekhri
Mr. Paul Jai Sekhri
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
5.00K
--
Dr. Raymond Cheong, M.D., Ph.D.
Dr. Raymond Cheong, M.D., Ph.D.
Independent Director
Independent Director
4.82K
+61.94%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Srinivas Akkaraju, M.D., Ph.D.
Dr. Srinivas Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
5.23K
--
Dr. Srinivas Akkaraju, M.D., Ph.D.
Dr. Srinivas Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
5.23K
--
Dr. Srinivas Akkaraju, M.D., Ph.D.
Dr. Srinivas Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
5.23K
--
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Independent Director
Independent Director
5.01K
+57.13%
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Independent Director
Independent Director
5.01K
+57.13%
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Independent Director
Independent Director
5.01K
+57.13%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de vTv Therapeutics Inc?
Los cinco principales accionistas de vTv Therapeutics Inc son: Dr. Srinivas Akkaraju, M.D., Ph.D.
¿Cuántas instituciones poseen acciones de vTv Therapeutics Inc (VTVT)?
A fecha de 2026Q1, 47 instituciones poseen acciones de vTv Therapeutics Inc, con un valor de mercado combinado de aproximadamente 1.41M, lo que representa el 35.82% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 186915.00.